Importance Use of tyrosine kinase inhibitors (TKIs) is the standard therapy for epidermal growth factor receptor ( EGFR )–mutated non–small cell lung cancer (NSCLC) with brain metastases. Several studies have shown that adding chemotherapy to EGFR-TKIs could improve progression-free survival (PFS) in patients -mutant advanced NSCLC; however, efficacy these agents metastases remains unclear. Objective To investigate and safety gefitinib plus (pemetrexed platinum) compared alone untreated...

<title>Abstract</title> Primary pulmonary lymphoepithelioma-like carcinoma (pLELC) is a relatively uncommon variant of primary non-small cell lung cancer, and its etiology still largely unexplored. Objective: The aim this study to investigate the underlying mechanisms potential therapeutic targets associated with pLELC. patients diagnosed advanced pLELC were retrospectively collected subjected proteomics metabonomics analysis. Finally, patient-derived xenograft (PDX) model was constructed...

Abnormal microRNA expression is closely related to cancer occurrence and development. miR-365a-3p plays an oncogenic role in skin cancer, but its lung remains unclear. In this study, we aimed investigate underlying molecular mechanisms cancer. Western blot real-time quantitative PCR (qPCR) were used detect the of adenocarcinoma cell lines. The effects on proliferation, migration, invasion also explored vitro. potential that targets USP33 was determined by dual luciferase reporter assay...

Abstract Background Due to the blood-brain barrier, plasma is not an ideal source evaluate genetic characteristics of central nervous system tumors. Thus, cerebrospinal fluid (CSF) becoming alternative biopsy type landscape intracranial We aimed explore profiles CSF-derived circulating tumor DNA (ctDNA) predict responses and monitor mutational evolution during treatment non-small cell lung cancer (NSCLC) patients with brain metastases. Methods conducted a prospective study 92 newly diagnosed...

Lung cancer is one of the most common causes brain metastases and always associated with poor prognosis. We investigated immunophenotypes primary lung tumors paired metastases, as well in synchronous group (patients upon initial diagnosis) metachronous developed during course their disease). RNA sequencing eighty-six samples from 43 patients was conducted to analyze tumor immune microenvironment. Our data revealed that matched compared exhibited reduced infiltrating lymphocytes (TILs), a...

Second-generation anaplastic lymphoma kinase (ALK) tyrosine inhibitors (TKIs) have significantly improved clinical outcomes in patients with advanced ALK-positive non-small cell lung cancer (NSCLC), but responses vary widely. In this study, the impacts of ALK fusion variants, concomitant mutations, and PD-L1 expression on response were evaluated receiving second-generation TKIs.We retrospectively enrolled 193 ALK-rearranged NSCLC who received TKIs at Sun-yat Sen University Cancer Center from...

Background: Currently, there is a lack of well-established markers to predict the efficacy chemoimmunotherapy in small-cell lung cancer (SCLC). Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR), advanced inflammation index (ALI) and prognostic nutritional (PNI) are associated with prognosis several tumors, whereas their predictive role SCLC remains unclear. Methods: A retrospective study was conducted at Sun Yat-sen University Cancer Center, involving extensive-stage...

Highlights•Whether PK-guided pembrolizumab in advanced NSCLC is a rational therapeutic strategy.•Pembrolizumab administration under was an alternative strategy.•Personalized optimal treatment of can reduce economic toxicity.AbstractIntroductionPembrolizumab recommended with fixed dose 200 mg 3-weekly. We performed this study to explore the clinical efficacy and safety pharmacokinetic (PK)-guided non-small cell lung cancer (NSCLC).MethodsIn prospective exploratory study, we enrolled patients...

Abstract Purpose Primary pulmonary lympho-epithelioma-like carcinoma (PPLELC) is a rare subtype of primary non-small cell lung cancer (NSCLC). Currently, there still lack research data on anti-angiogenic therapy advanced PPLELC. The purpose this study was to investigate the efficacy and safety combined with chemotherapy compared traditional for these patients. Methods Advanced PPLELC patients admitted six grade A hospitals from January 2013 2021 were selected. received (AT group) or (CT...

Background Immunotherapy has shown intracranial efficacy in non-small cell lung cancer (NSCLC) patients with brain metastases. However, predictive biomarkers for response to immunotherapy are lacking. This post-hoc analysis aimed explore the potential of immunological cytokines cerebrospinal fluid (CSF) predict tumor

Abstract Thymic carcinoma (TC) is a rare malignant tumor with poor prognosis, and there currently limited data on the use of immunotherapy in patients unresectable TC. In this study, TC diagnosed from January 2017 were retrospectively collected multiple centers. Treatment response, progression‐free survival (PFS), overall (OS), survival‐independent prognostic factor, adverse events (AEs) further analyzed. As result, total 93 enrolled, which 54 received first‐line chemotherapy, 39...

Brain metastases (BM) are highly prevalent and associated with a poor prognosis in patients small cell lung cancer (SCLC). However, the evidence regarding efficacy of immune checkpoint inhibitors (ICIs) combination chemotherapy for SCLC BM remains limited. Therefore, objective this study is to evaluate whether addition ICIs confers survival benefits BM.

To investigate the role of USP33 as an independent prognostic marker in regulation SLIT2/ROBO1 signaling pathway to inhibit lung adenocarcinoma invasion and metastasis.The expression 20 specimens was detected by qPCR immunohistochemistry. A549 SPC-A-1 cells with small interfering RNA (siRNA)-mediated silencing were examined for changes metastasis abilities using scratch assay Matrigel assay. Western blotting used detect SLIT2 ROBO1 after interleukin-6 (IL-6) stimulation.qPCR...

9095 Background: Combination of tyrosine kinase inhibitor (TKI) and chemotherapy has shown improved clinical outcomes in advanced epidermal growth factor receptor ( EGFR) mutated non-small cell lung cancer (NSCLC) patients. We conducted this phase 3, randomized, controlled trial to further investigate the efficacy safety gefitinib combined with EGFR NSCLC patients brain metastases. Methods: Treatment-naïve, confirmed metastases sensitive were screened from six centers China. The eligible...

2023 Background: Cerebrospinal fluid (CSF) can be used as a type of liquid biopsy to detect brain tumors. We aimed explore the genetic profiles CSF-derived circulating tumor DNA (ctDNA) predict intracranial response and monitor mutational evolution during systemic treatment in non-small cell lung cancer (NSCLC) patients with metastases. Methods: conducted aprospective study 92 newly diagnosed NSCLC Paired CSF plasma samples were collected at baseline, 8 weeks after initiation, disease...

2040 Background: Immunotherapy has been the standard first-line therapy in patients with advanced non-small cell lung cancer (NSCLC), and shown a certain efficacy for brain metastases. however, appropriate predictive biomarkers intracranial tumor response to immunotherapy are unclear. We conducted this prospective study explore immunological cytokines cerebrospinal fluid (CSF) predict NSCLC Methods: prospectively enrolled treatment-naive, EGFR/ALK wild-type metastases study. Patients...

Abstract Optimal first‐line treatment approaches for non‐small cell lung cancer (NSCLC) with brain metastases (BMs) without driver gene alterations remain unclear. Recently, some studies preliminarily have suggested that immunotherapy plus chemotherapy (ICI+Chemo) may be superior to bevacizumab (Beva+Chemo). However, no study directly compares the effectiveness of two NSCLC patients BMs alterations. are retrospectively identified lacking sensitizing mutations, and divided into ICI+Chemo...

Using neutron diffraction and magnetic measurement, we have measured the canting angle of iron spin in Nd15Fe78B7 compound with powder samples. The spins rotate away from c-axis by 26°34' at 77K.

e21161 Background: Pembrolizumab with or without chemotherapy has become the standard therapy in advanced non-small cell lung cancer (NSCLC), a fixed dose of 200mg every 3 weeks. We performed this study to explore clinical efficacy and safety pharmacokinetic (PK)-guided pembrolizumab administration NSCLC. Methods: In prospective, open-label, single-arm exploratory study, we enrolled NSCLC patients sensitizing EGFR ALK mutation Sun Yat-Sen University Cancer Center. Eligible received weeks for...

Abstract Purpose: Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare subtype of primary non-small cell lung cancer (NSCLC). Currently, there still lack research data on anti-angiogenic therapy advanced PPLELC. The purpose this study was to investigate the efficacy and safety combined with chemotherapy compared traditional for these patients.Methods: Advanced PPLELC patients admitted six grade A hospitals from January 2013 2021 were selected. received chemotherapy(AT group)...